Therapeutic Benefits of Alpha-Lipoic Acid Supplementation in Diabetes Mellitus : A Narrative Review
Elevated oxidative stress is a common denominator between pathways implicated in the pathogenesis of diabetes mellitus and diabetes complications, prompting the use of antioxidant compounds in diabetes therapy. Alpha-lipoic acid (ALA), has been investigated for its role as a potent antioxidant in diabetes treatment and the results from clinical trials indicate improved glucose metabolism, reduced oxidative stress, improved endothelial dysfunction, a decline in platelet reactivity and moderate improvements to weight loss yet conflicting data regarding insulin metabolism. ALA inhibits nuclear factor kappa B (NFkB), chelates divalent transient metal ions and induces the expression of adenosine monophosphate-activated protein kinase (AMPK). This narrative review explores the results from clinical trials investigating the role of ALA in the treatment of diabetes mellitus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of dietary supplements - 19(2022), 4 vom: 23., Seite 566-586 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeffrey, Sam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
73Y7P0K73Y |
|---|
| Anmerkungen: |
Date Completed 23.06.2022 Date Revised 23.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/19390211.2021.2020387 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334754771 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334754771 | ||
| 003 | DE-627 | ||
| 005 | 20231225224402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19390211.2021.2020387 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334754771 | ||
| 035 | |a (NLM)34939534 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeffrey, Sam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Benefits of Alpha-Lipoic Acid Supplementation in Diabetes Mellitus |b A Narrative Review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2022 | ||
| 500 | |a Date Revised 23.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Elevated oxidative stress is a common denominator between pathways implicated in the pathogenesis of diabetes mellitus and diabetes complications, prompting the use of antioxidant compounds in diabetes therapy. Alpha-lipoic acid (ALA), has been investigated for its role as a potent antioxidant in diabetes treatment and the results from clinical trials indicate improved glucose metabolism, reduced oxidative stress, improved endothelial dysfunction, a decline in platelet reactivity and moderate improvements to weight loss yet conflicting data regarding insulin metabolism. ALA inhibits nuclear factor kappa B (NFkB), chelates divalent transient metal ions and induces the expression of adenosine monophosphate-activated protein kinase (AMPK). This narrative review explores the results from clinical trials investigating the role of ALA in the treatment of diabetes mellitus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a alpha-lipoic acid | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a glucose metabolism | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Thioctic Acid |2 NLM | |
| 650 | 7 | |a 73Y7P0K73Y |2 NLM | |
| 700 | 1 | |a Isaac Samraj, Punitha |e verfasserin |4 aut | |
| 700 | 1 | |a Sundara Raj, Behin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of dietary supplements |d 2008 |g 19(2022), 4 vom: 23., Seite 566-586 |w (DE-627)NLM192571656 |x 1939-022X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:4 |g day:23 |g pages:566-586 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/19390211.2021.2020387 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 4 |b 23 |h 566-586 | ||